Table 2

Treatment outcomes by study population and era

Adults
(≥16 years) n=3313
Children
(<16 years) n=417
Elderly subgroup*
(≥65 years) n=783
Rate of 1-year remission within 1 or 2 years of treatment
Patients with at least one period of
1-year remission†, n (%)
2430 (73.3)317 (76.0)536 (68.5)
 Of these patients, at least one relapse†, n (%)1362 (56.0)163 (51.4)310 (57.8)
1-year period of remission 1 year from treatment start (KM estimate)35.2%40.1%36.3%
 Era 1‡31.6%36.4%31.5%
 Era 2‡34.7%41.9%32.8%
 Era 3‡42.0%40.8%47.3%
1-year period of remission within 2 years of treatment start (KM estimate)75.3%75.9%78.4%
 Era 1‡71.9%73.0%76.1%
 Era 2‡75.3%78.3%78.2%
 Era 3‡81.4%72.8%81.7%
Rate of refractoriness within 3 years of starting first AED treatment
Patients refractory 3 years from start of treatment (KM estimate)17.5%23.8%11.9%
 Era 1‡17.3%20.8%11.1%
 Era 2‡17.4%24.3%13.4%
 Era 3‡17.6%(n<10)11.2%
  • Era 1: 1 April 2003 to 31 August 2007 (first NICE guidance); era 2: 1 September 2007 to 31 December 2011 (SANAD); era 3, 1 January 2012 to 31 May 2016 (second NICE guidance).

  • *Elderly patients are a subset of the adult patient population.

  • †Raw figures, not adjusted for differential follow-up between eras.

  • ‡Number of patients diagnosed in eras 1, 2 and 3, respectively, and received treatment: adults, n=1097, 1254 and 962; children, n=110, 204 and 103; elderly subgroup, n=234, 291 and 258.

  • AED, antiepileptic drug; KM, Kaplan-Meier estimate; NICE, National Institute for Health and Care Excellence; SANAD, Standard and New Antiepileptic Drugs.